Laura Airas
Professor of Neuroimmunology, MD, PhD
laura.airas@utu.fi Itäinen Pitkäkatu 4 Turku ORCID identifier: https://orcid.org/https://orcid.org/0000-0002-9751-5881 |
Neurology; Neuroimmunology; Multiple sclerosis; PET-imaging; MRI; Drug development
Multiple sclerosis research, @multiplesclerosisresearchfinland, Neuroinflammation research, INFLAMES Flagship
Laura Airas is an internationally recognized expert in multiple sclerosis (MS) and has served as Professor of Neuroimmunology at the University of Turku since 2017. She also practices clinically as a neurologist at Turku University Hospital, specializing in the care of MS patients.
Professor Airas earned her MD from the University of Turku in 1991 and completed her PhD in immunology and cell biology under Professor Sirpa Jalkanen. Her dissertation was recognized with a special distinction from the University of Turku. She became a specialist in neurology in 2001 and was appointed Associate Professor (docent) in 2007.
Her international experience includes serving as a Visiting Professor at Yale University in 2016–2017. In 2015, she was awarded the prestigious Grant for Multiple Sclerosis Innovation (GMSI).
Professor Airas is a respected member of the international scientific community. She serves as a reviewer for major neurology and neuroimmunology journals and funding agencies, and is a frequent invited speaker at national and international scientific events.
Professor Airas leads a translational and patient-centered research group focusing on the pathophysiology of progressive MS and the development of novel therapeutic strategies. Her research integrates cutting-edge imaging techniques (PET and MRI), biomarker discovery, and genetic analysis to investigate the role of glial cells in brain neurodegeneration.
Her multidisciplinary group of about 20 members includes physicians, biomedical scientists, biosiatisticians, and students. They collaborate widely with national and international partners in PET imaging, immunology, drug development, and neuroscience.
The research is funded by:
- Research Council of Finland
- State Research Funding (VTR)
- Jane and Aatos Erkko Foundation
- U.S.-based organizations including the U.S. Department of Defense, National MS Society, and the Progressive MS Alliance
The group is a member of the InFLAMES Flagship at the University of Turku, where Professor Airas also serves on the leadership team.
In addition to her academic work, Professor Airas has been the Principal Investigator in numerous international multicenter clinical trials. She currently leads two investigator-initiated trials targeting microglial activation to slow down progression of MS.
Professor Laura Airas is actively engaged in teaching at the University of Turku. She lectures in neurology and neuroimmunology for students in the medical and biomedical degree programmes and trains specialist physicians in neurology.
Her teaching approach emphasizes patient-centeredness, integration of clinical care and research, and the application of up-to-date scientific knowledge. She brings insights from the latest breakthroughs in neuroimmunology and clinical trial methodology directly into the classroom.
Professor Airas also supervises PhD candidates and has served as the primary supervisor for several completed doctoral theses. In addition, she contributes to postgraduate education programmes for neurology specialists and neuroscience professionals. She is a sought-after lecturer at both national and international medical education events.
- Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis (2025)
- Nature Medicine
(A1 Refereed original research article in a scientific journal) - Generics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists (2025)
- European Journal of Neurology
(A2 Refereed review article in a scientific journal ) - Integrating TSPO-PET imaging with metabolomics for enhanced prognostic accuracy in multiple sclerosis (2025)
- BMJ neurology open
(A1 Refereed original research article in a scientific journal) - Microglia positron emission tomography and progression in multiple sclerosis: thalamus on fire (2025)
- Brain Communications
(A1 Refereed original research article in a scientific journal) - Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis (2025)
- Journal of Neurology, Neurosurgery and Psychiatry
(A1 Refereed original research article in a scientific journal) - A Novel Comprehensive Epigenomic Liquid Biopsy Assay Reveals Disease Biology in Multiple Sclerosis Patients from 1 mL of Plasma (2024)
- Multiple Sclerosis
(Abstract) - A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis (2024)
- Therapeutic Advances in Neurological Disorders
(A2 Refereed review article in a scientific journal ) - MS-taudin monet kasvot (2024)
- Turun Sanomat
(E1 Popularised article) - P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study (2024)
- EJNMMI Research
(A1 Refereed original research article in a scientific journal) - Plasma CHI3L1 associates with increased TSPO-PET measurable microglial activation in patients with progressive multiple sclerosis (2024)
- Multiple Sclerosis
(Poster) - Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals (2024)
- Frontiers in Neurology
(A1 Refereed original research article in a scientific journal) - Smouldering-Associated Worsening in Multiple Sclerosis : An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions (2024)
- Annals of Neurology
(A2 Refereed review article in a scientific journal ) - Synaptic density in multiple sclerosis: An in vivo study using [11C]UCB-J-PET imaging (2024)
- Multiple Sclerosis
(Abstract) - TSPO-PET-measurable microglial activity remains unaltered in cladribine-treated RRMS patients (2024)
- Multiple Sclerosis
(Poster) - Adenosine A2A receptor availability in cerebral gray and white matter of patients with Parkinson's disease (2023)
- Parkinsonism and Related Disorders
(A1 Refereed original research article in a scientific journal) - Adenosine A2A receptor availability in patients with early- and moderate-stage Parkinson’s disease (2023)
- Journal of Neurology
(A1 Refereed original research article in a scientific journal) - Association of serum neurofilament light with microglial activation in multiple sclerosis (2023)
- Journal of Neurology, Neurosurgery and Psychiatry
(A1 Refereed original research article in a scientific journal) - Diagnosis and treatment of progressive multiple sclerosis: A position paper (2023)
- European Journal of Neurology
(A1 Refereed original research article in a scientific journal) - Early prognosticators of later TSPO-PET-measurable microglial activation in multiple sclerosis (2023)
- Multiple Sclerosis and Related Disorders
(A1 Refereed original research article in a scientific journal) - Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis (2023)
- European Journal of Neurology
(A1 Refereed original research article in a scientific journal)